natgillin/translations-raw huggingface dataset:
The information system according to any of the preceding claims, wherein the reflector comprises a reflective surface having an angle for total reflection within a range of 20 to 70, preferably 30 to 60, and most preferably 40 to 55 degrees with respect to the optical axis of the optical element to reflect the sunlight to the absorber. 
Optički element (OP) u skladu sa bilo kojim od prethodnih patentnih zahtjeva, pri čemu reflektor sadrži reflektirajuću površinu koja ima kut za totalnu refleksiju unutar opsega od 20 do 70, poželjno 30 do 60, i najpoželjnije 40 do 55 stupnjeva u odnosu na optičku os optičkog elementa za reflektiranje sunčeve svijetlosti.
This mechanism was recently shown to be operant in the well demonstrated immunosuppression of FTY 720, a drug currently submitted to clinical trials in the prevention of organ transplant rejection (Matioubian et al, Nature, 427, pp. 355-360, 2004). 
Nedavno se pokazalo da ovaj mehanizam djeluje kod dobro demonstriranc imunosuprcsije pod utjecajem FTY 720, što je lijek koji trenutno prolazi kroz klinička ispitivanja sprječavanja odbacivanja organskih presadaka (Matioubian 1 drugi: Nature, 427, str. 355-360, (2004.)).
Alternatively, permeation of buprenorphine may be enhanced by occlusion of the dosage form after application to the desired site on the patient with, e.g. 
Alternativno, prodiranje buprenorfina može se poboljšati okluzijom doze nakon nanošenja na željeno mjesto na pacijentu, npr.
(wherein RE6 is selected from substituent group A, m is an integer of 0 or more, and substituent group A is same meaning as those of item 1′) and; 
(gdje svaki R* je ista ili su različite skupine odabrane iz supstituentske skupine A, m je cijeli broj od 0 naviše, a Supstituentska skupina A ima isto značenje kao što je navedeno u zahtjevu 20
is independently selected from optionally substituted C1-C8 alkyl, optionally substituted C6-C12 acryl, optionally substituted hetero C5-C10 aryl, optionally substituted C3-C10 cycloalkyl, and optionally substituted hetero C3-C10 cycloalkyl, wherein said optional substituents are one to three R10 groups; 
R' je nezavisno odabran od proizvoljno supstituiranog C;-Cg alkila, proizvoljno supstituiranog Cy-C,> arila, proizvoljno supstituiranog hetero Cs-Cio_ arila, proizvoljno supstituiranog C3-Cjo_ Cikloalkila i proizvoljno supstituiranog hetero C2-C1g Cikloalkila, pri čemu su navedeni nezavisni supstituenti jedna do tri R* skupine;
The plunger tube or cylinder is denoted by 14, while the plunger itself comprises a plunger-rod 12 and a plunger end 13. 
Cijev klipa ili cilindar je označen s 14, dok sam klip sadržava spojnu šipku klipa 12 1 kraj klipa 13.
Brief Summary of Embodiments of the Inention 
Broj objave europskog patenta:
An oil-in-water emulsion comprising mometasone or a pharmaceutically acceptable derivative thereof and a C4 alkane-diol, which may be linear or branched, and the concentration of the C4 alkane-diol is from 20 to 45% w/w. 
Emulzija ulje-u-vodi naznačena time da sadrži mometazon ili njegov farmaceutski prihvatljiv derivat i C, alkan-diol, koji može biti ravan ili razgranat, te je koncentracija Ca alkan-diola od 20 do 45% w/w.
The process of claim 1, wherein said first quantity of HPMC is approximately 40 to 60% of the total quantity. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je navedena prva količina HPMC otprilike 40 do 60% od ukupne količine.
The feed according to claim 1 or 2, characterized in that the fatty acid mixture contains at least 80% palmitic acid and at most 20% stearic acid, preferably at least 95% palmitic acid and at most 5% stearic acid.; and/or the fatty acid mixture contains the following fatty acids, in %: 
Životinjska hrana prema zahtjevu 1 ili 2, naznačeno time da mješavina masnih kiselina sadrži barem 80% palmitinske kiseline 1 najviše 20% stearične kiseline, poželjno barem 95% palmitinske kiseline i najviše 5% stearične kiseline; i/ili mješavina masnih kiselina sadrži sljedeće masne kiseline u %:
said anti-angiogenic agent is selected from neutralizing antibodies, antisense RNA, siRNA, RNAi, RNA aptamers or ribozymes directed against a gene encoding VEGF, a gene encoding a VEGF receptors, VEGF, or a VEGF receptor; or a variant of VEGF possessing antagonistic properties against VEGF; and 
Oblik prema zahtjevu 33 ili 34, gdje se anti-angiogenično sredstvo izabire između neutralizirajućih protutijela, nekodirajuće RNA, siRNA, RNAi, RNA aptamera ili ribozima usmjerenih protiv gena koji kodira VEGF, gena koji kodira VEGF receptore, VEGE, ili VEGF receptor; ili varijante VEGF koja ima antagonistička svojstva protiv VEGF.
The results of LAL, TOC, Bio Burden and pH analyses performed on samples transferred after each rinsing-phase are shown in table 3: 
Rezultati LAL-a, TOC-a, biološkog opterećenja i pH analiza koji su provedeni na uzorcima koji su izdvojeni nakon svake faze ispiranja prikazani su u tablici 3:
extracting a fish material with an extractant solvent; 
- < ekstrahiranje ribljeg materijala s ekstrahirajućim otapalom;
Mould system according to any of the preceding claims, wherein the support device (5) comprises bars (10) which extend generally parallel beneath the mould plate (10), each bar being supported by means of at least two extendable and retractable support legs (8) which may be adjusted under computer control. 
Sustav kalupa u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu potporna naprava (5) obuhvaća stupce (10) koji se uglavnom produžuju paralelno ispod ploče kalupa (10), svaki je stupac poduprt pomoću barem dvije potporne noge (8) koje se mogu produljiti 1 uvući podešavanjem pod nadzorom računala,
The pharmaceutical composition for use according to any one of claims 2, 3 or 5-14, wherein the periodic administration of glatiramer acetate is effected daily. 
Farmaceutski sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 2,3 ili 5-14, naznačen time, da so periodičko davanje glatiramer acetata provodi dnevno.
After stirring at room temperature for 1h the solvent was removed by evaporation under reduced pressure, and the reaction mixture was re-dissolved in 1,2-dichloroethane (15 mL). 
Nakon miješanja na sobnoj temperaturi kroz 1 sat otapalo se ukloni uparavanjem pri sniženom tlaku, i reakcijska smjesa se ponovno otopi u 1,2-dikloroetanu (15 ml).
Reclosing system according to claim 1 or 2, wherein the external longitudinal profiles of said lateral portions (6) lie on a common line of rectilinear continuation, said tongue (4) not being intercepted by said line. 
Sustav ponovnog zatvaranja prema zahtjevu 1, naznačen time da vanjski uzdužni profili navedenih bočnih dijelova (6) leže na zajedničkoj liniji pravocrtnog nastavka, te navedeni jezik (4) nije presječen sa navedenom linijom.
Aspect: Access point according to aspect 16, wherein the further mobile communication technology is a technology according one of the IEEE-802.11-family of mobile communication standards. 
Pristupna točka prema zahtjevu 11, pri čemu je druga mobilna komunikacijska tehnologija tehnologija prema jednom iz IEEE-$02.11-seta standarda za mobilnu komunikaciju.
An antibiotic macrolide compound of the general formula I: 
Antibiotski makrolidni spoj opće formule I: gdje
Preferred substituted C5-6 cycloalkyl groups are cyclopentyl and cyclohexyl, substituted with 1 or 2, especially 1, groups selected from halo, hydroxy, methyl, trifluoromethyl, and methoxy, especially fluoro, chloro, or methyl. 
Prefcriranc supstituiranc C5-6 cikloalkilne skupinc su ciklopentil i ciklohcksil, supstituirane sa 1 ili 2, posebno 1, skupinama odabranim od halo, hidroksi, metil, triflorometil, i metoksi, posebno floro, kloro ili metil.
represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C1-4 alkyl group, a C1-4 alkoxy group, or a halogen atom; represents a benzene ring or a naphthalene ring; the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a methylendioxy group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-4 alkoxy group, a nitro, a cyano, an amino, a C1-5 monoalkylamino group or a C2-10 dialkylamino group; 
R1 znači 2-, 3- ili 4-piridinski prsten ili 2-, 4- ili 5-pirimidinski prsten, gdje su ti prsteni izborno supstituirani s C,u alkilnom skupinom, C;.4 alkoksi skupinom ili atomom halogena; R2 predstavlja benzenski prsten ili naftalenski prsten, gdje su ti prsteni izborno supstituirani s 1 do 4 supstitucnta, koje sc bira između Cis alkilnc skupine, metilendioksi skupine, atoma halogena, perhalogenirane Ci.» alkilne skupine, halogenirane C;3 alkilne skupine, hidroksilne skupine, Ca alkoksi skupine, nitro, cijano, amino, C;.s monoalkilamino skupine ili C210 dialkilamino skupine;
applying a further layer of the coating material over the first layer to form a second layer; and 
naneseni obložni materijal, učvršćuje kao drugi sloj pomoću IR-sušenja ili pomoću konvencionalnog sušenja.
Rb is selected from the group consisting of H, halogen, hydroxyl, cyano and C1-C6 alkyl (e.g., H); is H or C1-C6 alkyl; 
R4 1 Rs su svaki neovisno odabrani od skupine koja se sastoji od H, C,-C4 alkila, X 1 -Cy-Cg alkilen-X, pri čemu je X odabran od skupine koja se sastoji od (1) -C;:-Ceg cikloalkila;
It is understood that the scope of combination-therapy of the compounds of the present invention with other pharmaceutical agents is not limited to those listed herein, supra or infra, but includes in principle any combination with any pharmaceutical agent or pharmaceutical composition useful for the treatment of diseases, conditions or disorders that are linked to metabolic-related disorders. 
Razumljivo je da doseg kombinirane terapije spojeva prikazanog izuma s ostalim farmaceutskim sredstvima nije ograničen onima navedenim u ovom tekstu, supra i infra, već uključuje u principu bilo koju kombinaciju s bilo kojim farmaceutskim pripravkom korisnim za liječenje oboljenja, stanja ili poremećaja koji su povezani s metabolički pripadajućim poremećajima.
means for constellation-mapping bits of signaling data into preamble symbols; means for constellation-mapping bits of the service data into service data symbols; means for building at least one data slice based on the service data symbols; 
mapiranje podatkovnih bitova preambule u simbole preambule, te bitove podatkovnog servisa u simbole podatkovnog servisa; sastavljanje barem jednog podatkovnog odsječka na temelju simbola podatkovnog servisa;
A toothbrush according to claim 10 in which the translating means comprises at least one cam connected to the head and a corresponding follower connected to the drive shaft. 
Četkica za zube (10) sukladno zahtjevu 10 pri čemu sredstvo za prijenos sadrži barem jedan ekscentar spojen na glavu (12) i odgovarajući slijednik spojen na pogonsku osovinu (20).
The peptide for use according to Claim 1, wherein said peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu navedeni peptid uključuje nepeptidne veze.
a substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl; 
(a) supstituirani ili nesupstituirani fenil ili supstituirani ili nesupstituirani naftil;
a polypeptide consisting of the sequence set forth in amino acids 19 through 134 of SEQ ID NO:2, except for a single amino acid substitution at the position corresponding to position 28 of SEQ ID NO:2, and a single amino acid substitution at the position corresponding to position 44 of SEQ ID NO:2, wherein the substitution at position 28 is selected from the group consisting of W and Y, and the substitution at position 44 is T; 
polipeptid koji se sastoji od slijeda iznijetog u aminokiseline 19 do 134 u SEQ ID NO:2, osim jedne aminokiselinske zamjene na položaju koja odgovara položaju 28 u SEQ ID NO:2 i jedne aminokiselinske zamjene na položaju koja odgovara položaju 44 u SEQ ID NO:2, gdje se zamjenu na položaju 28 bira iz skupine koju čine W i Y, a zamjena na položaju 44 je T;
The method of claim 1, wherein the endogenous mouse Vλ gene segments of the second endogenous Vλ-Jλ-Cλ gene cluster have been replaced with a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ3-12 gene segment to a human Vλ3-1 gene segment. 
Miš prema patentnom zahtjevu 1, naznačen time što sadrži četiri humana segmenta gena JA, naznačen time, što je poželjno da četiri humana segmenta gena JA budu JM, JX2, J23 1 JA7.
X is L -Y-glutamyl or L -Y-glutamylglycyl; Y is H, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; and Z is C5-9 alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl. 
X je L-y-glutamil, ili L-y-glutamilglicil; Y je H, po izboru supstituiran alkil, po izboru supstituiran heteroalkil, po izboru supstituiran aril, po izboru supstituiran aralkil, po izboru supstituiran heteroaril, ili po izboru supstituiran heteroaralkil; i Z je Cs.» alkil, po izboru supstituirani aril, po izboru supstituiran aralkil, po izboru supstituirani heteroaralil, ili po izboru supstituirani heteroaralkil; ili njegov C1.19 alkil, fenil-C1.3 alkil, ili (C5.g heteroaril)-C,.; alkil mono- ili di-ester; ili sol spoja ili njegov mono- ili di-ester.
The data are summarized in the FIG. 
Podaci su sumirani na slici 1.
A compound of formula (I) as defined in claim 1 or an N -oxide thereof, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment and/or prevention of a disorder for which the administration of a selective PI3K inhibitor is indicated. 
Spoj formule (I) kako je definirano u zahtjevu 1 ili njegov N-oksid ili njegova farmaceutski prihvatljiva sol ili solvat, za upotrebu u liječenju i/ili prevenciji poremećaja za koje je mndicirana primjena selektivnog PI3K inhibitora.
Use according to claim 10 wherein the immune response to be stimulated is a CTL response, Th1 response, Th2 response, Th17 response or a Treg response. 
Uporaba prema zahtjevu 10, naznačena time, da imunološka reakcija koja se treba stimulirati, je CTL reakcija, Th1 reakcija, Th2 reakcija, Th17 reakcija ili Treg reakcija.
The remaining solid was again treated with EtOAc and HCl (5N aq.) 
Preostala krutina je ponovno tretirana sa EtOAc i HCI (SN aq.)
and at least one transformation unit for performing transformation is obtained from the coding unit of the current depth, wherein the at least one prediction unit is one of the symmetric partitions and the asymmetric partitions, 
naznačen time, da su simetrične particije razdvojene od barem jedne, koja ima visinu i širinu kodirajuće jedinice u skladu sa simetričnim omjerom, te su nesimetrične particije razdvojene od particije, koja ima širinu i visinu kodirajuće jedinice u skladu sa nesimetričnim omjerom.
is selected from H, alkyl, heteroalkyl, and arylalkyl; and R2 and R3 together with the nitrogen group form an aliphatic amine. 
R3 je izabran od H, alkil, heteroalkil 1 arilalkil grupe; 1 R2 1 Rs uzeti zajedno sa dušikovom grupom formiraju alifatični amin.
It is preferably a rigid construction, particularly where the fluid 12 is contained in a bag 14 in the container 13. 
On je ponajprije krute konstrukcije, posebno ako se fluid 12 nalazi u vrećici 14 u spremniku 13.
Racemization of (R)-2-Isobutyl-succinonitrile Using DBU The racemization of (R)-2-isobutyl-succinonitrile was carried out on material recovered from bioconversion of racemic 2-isobutyl-succinonitrile with NIT-102 C2. 
Postupak u skladu s patentnim zahtjevom 1, gdje navedeni nepromijenjeni (R)-2-izobutilsukcinonitril iz koraka (b) se racemizira u racemični 2-izobutilsukcinonitril grijanjem s bazom u otapalu.
A process according to claims 1 or 6, wherein compound (I-a') is obtained by slow addition, under stirring, of gaseous bromine to a solvent-free equimolar amount of compound (I' -c) as defined in claim 13, at 0 - 10°C. 
Postupak prema zahtjevima I ili 6, gdje se spoj (T'-a) dobiva sporim dodavanjem plinovitog broma, uz miješanje, ekvimolarnoj količini spoja (I -c) bez otapala, kako je definirano u zahtjevu 13, na 0 - 10%C.
A synergistic herbicidal mixture as claimed in claims 1 to 2 in which the sulfonamide is selected from the group consisting of florasulam, flumetsulam, metosulam, penoxulam, cloransulam-methyl, and diclosulam, including their respective isomers as well as their respective environmentally compatible salts or esters or amides or other derivatives. 
Sinergijska herbicidna smjesa prema zahtjevima 1 do 2 gdje se sulfonamid izabire iz grupe koja obuhvaća florasulam, flumetsulam, metosulam, penoksulam, kloransulam-metil, i diklosulam, uključujući njihove odgovarajuće izomere kao i odgovarajuće, prihvatljive za okoliš, soli ili estere ili amide ili druge derivate.
using one of the channels as the second channel that currently has the highest data transfer rate. The method according to claim 1, wherein switching to the second channel is effected whenever the current effective data transfer rate of the second channel is greater than the data transfer rate of the first channel and the second channel has not been used within the last few seconds. 
Postupak temeljem zahtjeva 15, naznačen time da se promjena na drugom kanalu (4, 5) događa kada je trenutačna brzina prijenosa podataka drugog kanala (4, 5) veća nego brzina prijenosa podataka prvog kanala (3) a drugi kanal (4, 5) se ne koristi unutar zadnjeg perioda od nekoliko sekundi.
A compound of formula (I) as defined in claim 3 wherein: 
Spoj formule (I) u skladu s patentnim zahtjevima 1 do 3, naznačen time što:
The fuel gas supply system of a vessel according to claim 1, comprising a vaporizer configured to vaporize reliquefied boil-off gas. 
Sustav dobave pogonskog plina za brod prema zahtjevu 1, naznačen time da sredstvo za uplinjavanje je grijač.
The compound according to item 13′, or the pharmaceutically acceptable salt thereof or the solvate thereof, wherein R1a is hydrogen, halogen, hydroxy, carboxy, lower alkyl optionally substituted by substituent group C, lower alkenyl optionally substituted by substituent group C, lower alkyloxy optionally substituted by substituent group C, lower alkyloxycarbonyl optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, or —Z—N(RA1)(RA2) (substituent group C, RA1, RA2, and Z are same as those of item 13′). 
Spoj prema bilo kojem od zahtjeva 13 do 18, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time, da R* je vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, (Supstituentska skupina C ima isto značenje kao što je navedeno u zahtjevu 13).
The combination as defined in claim 3 wherein the lipid lowering agent is at least one agent selected from the group consisting of an MTP inhibitor, a CETP inhibitor, an HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibric acid derivative, an upregulator of LDL receptor activity, a lipoxygenase inhibitor and an ACAT inhibitor. 
Kombinacija prema patentnom zahtjevu 3, naznačena time što je sredstvo za snižavanje lipida najmanje jedno sredstvo izabrano iz grupe koju čine MTP inhibitor, CETP inhibitor, inhibitor HMG CoA reduktaze, inhibitor skvalen sintetaze, derivat fibrične kiseline, ushodni regulator LDL receptorne aktivnosti, inhibitor lipoksigenaze i ACAT inhibitor.
The method as in item 1, wherein a powder based balancing layer (4) comprising wood fibers and a thermosetting resin is applied on a rear side of the core (3). 
Postupak prema zahtjevu 1, naznačen time što dalje obuhvaća nanošenje balansirajućeg sloja temeljenog na prahu (4) koji sadrži drvena vlakna i termoreaktivnu smolu na stražnju stranu jezgre (3).
water for injection q.s. ad 100%. 
(f) vodu za injekcije q.s. do 100%.
The final molarity of the solution of sodium citrate was 0.175 M. Preparation of 2L of citrate buffer pH 4 approximately 0.1M: 850 ml of citric acid solution 0.2M were mixed with 650 ml of sodium citrate solution 0.2M in a volumetric flask of 2L. 
Krajnji molaritet otopine natrijcitrata bio je 0.175 M. Priprema 2L citratnog pufera pH 4 približno 0.IM: 850 mL otopine limunske kiseline 0.2M pomiješano je sa 650 mL otopine natrijcitrata 0.2M u volumetrijskoj posudi od 2L.
The compound of any one of claims 1 to 6 or the pharmaceutical composition of claim 7 for use according to any one of claims 6 to 14, wherein said compound or said pharmaceutical composition is to be administered orally. 
Spoj ili farmaceutski sastav za uporabu prema bilo kojem od zahtjeva 6 do 11, naznačen time što se navedeni spoj ili navedeni farmaceutski sastav koriste za oralnu primjenu.
Compound 24 was obtained as a yellow oil. 
Spoj 24 se dobiva kao žuto ulje.
an optimized viral polypeptide having the amino acid sequence set forth in SEQ ID NO:9, or 
optimizirani virusni polipeptid koji ima sekvencu amino kiselina prikazanu u SEQ ID NO:9, ili
The mixture was cooled and a small amount of sodium sulfite was added. 
Smjesa se ohladi i mala količina natrij sulfita
identifies a maximum in said cross-covariance values as corresponding to a time of arrival of said current pulse of output ultrasonic vibrations or 
(ii) identificira maksimum u navedenim vrijednostima unakrsne kovarijance kao odgovarajući vremenu dolaska navedenog trenutnog impulsa izlaza ultrazvučnih vibracija ili
a basic platform (1) connected through two ropes (2) to said power wing airfoil, said basic platform (1) being adapted to drive said wing airfoil and to convert an aeolian energy of said aeolian current into electrical or mechanical energy, said two ropes (2) being adapted to transmit forces from and towards said wing airfoil and to be used both for controlling a flight trajectory of said wing airfoil and for transmitting energy; 
- - baznu platformu (1) povezanu pomoću dva užeta (2) sa spomenutim aeroprofilom krila, pri čemu je spomenuta bazna platforma (1) prilagođena da pogoni spomenuti aeroprofil krila 1 da pretvara eolsku energiju spomenute eolske struje u električnu ili mehaničku energiju, dok su dva užeta (2) prilagođena da prenose sile sa spomenutog aeroprofila krila i na njega, kao 1 za korištenje i kontrolu putanje kretanja spomenutog aeroprofila krila 1 za prijenos energije;
Number of rats (n) 
(21) Broj predmeta:
A method of producing a mat according to claim 6, wherein said upper part of said moulding form comprises a pattern of closely spaced upwardly extending portions. 
Postupak proizvodnje otirača prema zahtjevu 6, naznačen time da navedeni gornji dio navedenog kalup sadrži uzorak blisko postavljenih dijelova koji se pružaju prema gore.
The installation process will be described in further detail in the following with reference to Figures 2a-2c that show a first embodiment of a beverage dispensing assembly. 
Postupak postavljanja će se sada opisati u daljnjim pojedinostima pomoću slika 2a-2c, koje prikazuju prvu izvedbu sklopa za točenje pića prema izumu.
Rref is the resistance of the reference resistor. The method according to claim 1, wherein in step a) the measurement of the time required for the at least one capacitor to reach a specified charge value is taken at least twice and the first charge time t1 is obtained as the mean of the measurements taken. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se u koraku a) mjerenje vremena potrebnog da najmanje jedan kondenzator dosegne specificiranu vrijednost nabijenosti provodi najmanje dvaput, a prvo vrijeme nabijanja t; se dobije kao prosjek provedenih mjerenja.
The use of Claim 9,wherein said AChE inhibitor is tacrine, donepezil, rivastigmine, or galantamine. 
Primjena Zahtjeva 10, naznačena time da navedeni inhibitor AChE pripada skupini takrina, donepezila, rivastigmina ili galantamina.